208 related articles for article (PubMed ID: 31183560)
1. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
Sato J; Tanaka R; Ishikawa H; Suzuki T; Shino M
Support Care Cancer; 2020 Mar; 28(3):1083-1088. PubMed ID: 31183560
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.
Tsukuura H; Miyazaki M; Morita T; Sugishita M; Kato H; Murasaki Y; Gyawali B; Kubo Y; Ando M; Kondo M; Yamada K; Hasegawa Y; Ando Y
Oncologist; 2018 Mar; 23(3):367-374. PubMed ID: 29038236
[TBL] [Abstract][Full Text] [Related]
3. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
[TBL] [Abstract][Full Text] [Related]
4. Economic and clinical burden of opioid-induced nausea and vomiting.
Nicholson BD
Postgrad Med; 2017 Jan; 129(1):111-117. PubMed ID: 27690715
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice.
Giusti R; Mazzotta M; Filetti M; Daniele G; Tsukuura H; Ficorella C; Porzio G; Marchetti P; Verna L
Support Care Cancer; 2019 Sep; 27(9):3531-3535. PubMed ID: 30684048
[TBL] [Abstract][Full Text] [Related]
6. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
7. Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study.
Satomi E; Kobayashi T; Ishikawa A; Arakawa S; Ishiki H; Amano K; Sakiyama N; Ariyoshi K; Kihara K; Oyamada S; Mizushima A
BMJ Open; 2024 Feb; 14(2):e076575. PubMed ID: 38417963
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment of cancer pain and opioid induced nausea and vomiting: online survey and comparison with current guidelines.
Gaertner J; Boehlke C; Kreye G; Fusi-Schmidhauser T; Mueller E; Roch C
Support Care Cancer; 2024 Jun; 32(7):436. PubMed ID: 38879720
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Opioid-Induced Nausea and Vomiting During Treatment of Moderate to Severe Acute Pain: A Randomized Placebo-Controlled Trial Comparing CL-108 (Hydrocodone 7.5 mg/Acetaminophen 325 mg/Rapid-Release, Low-Dose Promethazine 12.5 mg) with Conventional Hydrocodone 7.5 mg/Acetaminophen 325 mg.
Zuniga JR; Papas AS; Daniels SE; Patrick K; Muse DD; Oreadi D; Giannakopoulos HE; Granquist EJ; Levin LM; Chou JC; Maibach H; Schachtel BP
Pain Med; 2019 Dec; 20(12):2528-2538. PubMed ID: 30657996
[TBL] [Abstract][Full Text] [Related]
10. Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
Inagaki M; Kanemasa T; Yokota T
Curr Top Med Chem; 2020; 20(31):2830-2842. PubMed ID: 32648846
[TBL] [Abstract][Full Text] [Related]
11. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients.
Yamada T; Kanazawa Y; Aoki Y; Uchida E
J Nippon Med Sch; 2015; 82(2):100-5. PubMed ID: 25959201
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction.
Ishihara M; Ikesue H; Matsunaga H; Suemaru K; Kitaichi K; Suetsugu K; Oishi R; Sendo T; Araki H; Itoh Y;
Clin J Pain; 2012 Jun; 28(5):373-81. PubMed ID: 22156893
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients.
Ishihara M; Iihara H; Okayasu S; Yasuda K; Matsuura K; Suzui M; Itoh Y
Support Care Cancer; 2010 Dec; 18(12):1531-8. PubMed ID: 19921282
[TBL] [Abstract][Full Text] [Related]
16. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
[TBL] [Abstract][Full Text] [Related]
17. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Tsukuura H; Ando Y; Gyawali B; Matsumoto M; Sugishita M; Honda K; Urakawa H; Maeda O; Hasegawa Y
J Palliat Med; 2015 Nov; 18(11):977-80. PubMed ID: 26509390
[TBL] [Abstract][Full Text] [Related]
19. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary?
Kanbayashi Y; Hosokawa T
J Palliat Med; 2014 Jun; 17(6):683-7. PubMed ID: 24702605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
